Brought to you by 
Valeant buys Xcel for $280mm
Feb 2005
Executive Summary
To expand its North American neurology business, Valeant Pharmaceuticals International (neurology, dermatology, and infectious disease therapeutics) has agreed to acquire privately held Xcel Pharmaceuticals, a biotech company specializing in CNS drugs, for $280mm in cash, which includes the assumption of $44mm in debt.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Acquisition
- Payment Includes Cash
- Full Acquisition
- Payment Includes Stock
- Includes Contract
- Acquisition of Private Biotech
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com